Baseline characteristics of included trials
| Study | Stent type | Drug-eluting balloon | Control | Setting | Clopidogrel (mts) | Follow-up (mts) | MACE | TLR |
|---|---|---|---|---|---|---|---|---|
| Habara et al12 | DES | Sequent please | Uncoated balloon | Stable CAD | 3 | 6 | TLR, MI, death | Symptoms and stenosis >50% |
| PACCOCATH | 96% BMS | Paccocath DEB | Uncoated balloon | Stable CAD/ACS | 1 | 60 | TLR, MI, stroke, death | Symptoms and/or angiographic findings |
| PEPCAD 2 ISR | BMS | Sequent please | Taxus Liberte | Stable CAD/ACS | 3 (6 for control arm) | 12 | TLR, MI, ST, death | NA |
| PEPCAD DES | DES | Sequent please | Uncoated balloon | Stable CAD/ACS | 6 | 6 | TLR, MI, CV death | Symptoms and/or angiographic findings |
| ISAR-DESIRE | DES | Sequent please | Taxus Liberte, uncoated balloon | Stable CAD/ACS | 6 | 12 | TLR, death, MI | NA |
ACS, acute coronary syndrome; BMS, bare-metal stent; CAD, coronary artery disease; CV, cardiovascular; DES, drug-eluting stent; ISR, in-stent restenosis; MACE, definition of major adverse cardiac events; MI, myocardial infarction; Mts, months; Paccocath DEB, paccocath drug-eluting balloon, paclitaxel eluting, Bayer AG, Leverkusen, Germany; Sequent please, paclitaxel eluting balloon, Bayer, Germany; SES, sirolimus eluting stents; ST, stent thrombosis; TLR, target lesion revascularisation.